Trial Profile
To assess Biologic Switching among Non-Systemic Juvenile Idiopathic Arthritis Patients; A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Sep 2020
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Adalimumab (Primary) ; Anakinra (Primary) ; Belimumab (Primary) ; Canakinumab (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary) ; Rilonacept (Primary) ; Rituximab (Primary) ; Secukinumab (Primary) ; Tocilizumab (Primary) ; Ustekinumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Therapeutic Use
- 24 Sep 2020 New trial record
- 15 Sep 2020 Results published in The Journal of Rheumatology